



Curriculum Vitae

Personal information Tarec Christoffer El-Galaly

Work experience

1. Employer: Aarhus University Hospital
 - Start date: 2024
 - End date:
 - Position: Clinical Professor in Hematology
 - Country: Denmark
2. Employer: Aalborg University Hospital
 - Start date: 2021
 - End date: 2024
 - Position: Clinical professor in Hematology
 - Activities:
 - Country: Denmark
3. Employer: Roche
 - Start date: 2020
 - End date: 2021
 - Position: Medical Director and Clinical Science Lead
 - Activities: Idasanutlin and pentraxin_2
 - Country: Switzerland
4. Employer: Roche
 - Start date: 2019
 - End date: 2020
 - Position: Associate Medical Director
 - Activities: idasanutlin
 - Country: Switzerland
5. Employer: Aalborg University Hospital
 - Start date: 2015
 - End date: 2019
 - Position: Consultant Haematologist, Department of Haematology
 - Activities:
 - Country: Denmark
6. Employer: Aalborg University Hospital
 - Start date: 2014
 - End date: 2015
 - Position: Staff specialist, Department of Hematology
 - Activities:
 - Country: Denmark
7. Employer: Aalborg and Aarhus University Hospital
 - Start date: 2007
 - End date: 2014
 - Position: Specialist training positions
 - Activities:
 - Country: Denmark
8. Employer: Aalborg University
 - Start date: 2015
 - End date: 2019
 - Position: Associate professor
 - Activities:
 - Country: Denmark
9. Employer: Copenhagen and Aarhus University
 - Start date: 2021
 - End date:
 - Position: Biomedical Design Program, teaching
 - Activities:
 - Country: Denmark
10. Employer: Danish Region Quality Registers (RKKP)
 - Start date: 2021
 - End date:
 - Position: Consultant
 - Activities:
 - Country: Denmark
11. Employer: Danish Universities
 - Start date: 2017
 - End date:
 - Position: Adjudicator Danish Universities, internal medicine and emergency medicine
 - Activities:
 - Country: Denmark
12. Employer: Expert assessor in hematology, patient compensation assessments
 - Start date: 2016
 - End date:
 - Position: Expert assessor in hematology, patient compensation assessments
 - Activities:
 - Country: Denmark
13. Employer: National Board of Health
 - Start date: 2018

- End date: 2019
 - Position: Expert advisor in lymphoma, Second Opinion Committee Lymphoma
 - Activities:
 - Country: Denmark
14. Employer: Danish Medicines Agency
- Start date: 2015
 - End date: 2019
 - Position: Expert reviewer (hematology/oncology)
 - Activities:
 - Country: Denmark

Education and training

1. Subject: Aalborg University, Denmark
 - Start date: 2017
 - End date:
 - Qualification: Doctor of Medical Science (DMSc). "Staging and Disease Surveillance in Hodgkin and non_Hodgkin Lymphomas
 - Organisation: Highest academic degree in Denmark.
 - Country:
2. Subject: National Board of Health, Denmark
 - Start date: 2014
 - End date:
 - Qualification: Specialist in Internal Medicine/Haematology
 - Organisation:
 - Country:
3. Subject: Aarhus University, Denmark
 - Start date: 2007
 - End date:
 - Qualification: MD
 - Organisation:
 - Country:

Additional information

Publications

PUBLICATION LIST

Total number of peer reviewed publications: 158 (>80 within the past 5 years), including 27 first and 31 last authorships, 4 joint first and 9 joint last authorships (#/\$), 6 of those in Journal of Clinical Oncology (2 first and 4 last)

h-index: 30. Citations 2738 (Scopus, August 2024).

IF: Impact factor (2022, 2021 or 2020)

Peer reviewed publications

1. Articles

2024

1. Kristensen DT, Øvlisen AK, **El Galaly TC**, Roug AS. The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes. *Blood Adv.* 2024 Aug 20;bloodadvances.2024014173. doi: 10.1182/bloodadvances.2024014173. Epub ahead of print. PMID: 39163622.
2. Rasmussen LA, Vedsted P, Jensen H, Frederiksen H, **El-Galaly TC**, Kristensen IB, Virgilsen LF. Multiple myeloma: unplanned diagnostic pathways and association with risk factors and survival - a nationwide register-based cohort study in Denmark. *BMC Cancer.* 2024 Aug 12;24(1):998. doi: 10.1186/s12885-024-12706-8. PMID: 39134966. (IF 2020: 4.43)
3. Boellaard R, Buvat I, Nioche C, Ceriani L, Cottreau AS, Guerra L, Hicks RJ, Kanoun S, Kobe C, Loft A, Schöder H, Versari A, Voltin CA, Zwezerijnen GJC, Zijlstra JM, Mikhaeel NG, Gallamini A, **El-Galaly TC**, Hanoun C, Chauvie S, Ricci R, Zucca E, Meignan M, Barrington SF. International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline ¹⁸F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation. *J Nucl Med.* 2024 Aug 1;jnumed.124.267789. doi: 10.2967/jnumed.124.267789. Epub ahead of print. PMID: 39089812. (IF 2020: 10.057)
4. Rask Kragh Jørgensen R, Jakobsen LH, Eloranta S, Smedby KE, Pedersen RS, Jørgensen JM, Clausen MR, Brown P, Gang AO, Gade IL, Larsen TS, Jerkeman M, **El-Galaly TC**. Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish

- observational population-based study. *Eur J Haematol.* 2024 Jul 22. doi: 10.1111/ejh.14275. Epub ahead of print. PMID: 39037054. (IF 2020: 3.28)
5. Baech J, Jakobsen LH, Simonsen MR, Severinsen MT, Frederiksen H, Niemann CU, Brown P, Jørgensen JM, Dann EJ, Johnsen SP, **El-Galaly TC**. Survival outcomes and healthcare utilization between immigrant patients and Danish-born patients with hematological cancers: a Danish population-based study. *Eur J Epidemiol.* 2024 Jul 4. doi: 10.1007/s10654-024-01139-z. Epub ahead of print. PMID: 38963616.(IF 2022: 13.6)
 6. Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, Schou Pedersen R, Bjørn Poulsen C, Ortvad Gang A, Brown P, **El-Galaly TC**, Larsen TS. Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma. *Cancer Med.* 2024 Jun;13(12):e7239. doi: 10.1002/cam4.7239. PMID: 38888359; PMCID: PMC11184650. (IF 2020: 4.452)
 7. Rossetti S, Juul SJ, Eriksson F, Warming PE, Glinge C, **El-Galaly TC**, Haaber Christensen J, Kamper P, de Nully Brown P, Gislason GH, Vestmø Maraldo M, Tfelt-Hansen J, Hutchings M. Long-term cause-specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens-A nationwide Danish cohort study. *Br J Haematol.* 2024 Jun 12. doi: 10.1111/bjh.19586. Epub ahead of print. PMID: 38867552. (IF 2022: 6.5)
 8. Jemaa S, Ounadjela S, Wang X, **El-Galaly TC**, Kostakoglu L, Knapp A, Ku G, Musick L, Sahin D, Wei MC, Yin S, Bengtsson T, De Crespigny A, Carano RAD. Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography. *J Clin Oncol.* 2024 Jun 6;JCO2301978. doi: 10.1200/JCO.23.01978. Epub ahead of print. PMID: 38843483. (IF 2021: 50.717)
 9. Kristensen DT, Øvlisen AK, Jakobsen LH, Severinsen MT, Hannig LH, Starklint J, Hilsøe MH, Vallentin AP, Brabrand M, Hasselbalch HC, **El Galaly TC**, Roug AS. Metformin use and risk of myeloproliferative neoplasms - a Danish population-based case-control study. *Blood Adv.* 2024 May 17:bloodadvances.2023012266. doi: 10.1182/bloodadvances.2023012266. Epub ahead of print. PMID: 38758071. (IF 2022: 7.5)
 10. Vandtved JH, Øvlisen AK, Baech J, Weinrich UM, Severinsen MT, Maksten EF, Jakobsen LH, Glimelius I, Kamper P, Hutchings M, Specht L, Dahl-Sørensen R, Christensen JH, **El-Galaly TC**. Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study. *Br J Haematol.* 2024 Apr 29. doi: 10.1111/bjh.19475. Epub ahead of print. PMID: 38685596. (IF 2022: 6.5)
 11. Rask Kragh Jørgensen R, Bergström F, Eloranta S, Tang Severinsen M, Bjørø Smeland K, Fosså A, Haaber Christensen J, Hutchings M, Bo Dahl-Sørensen R, Kamper P, Glimelius I, E Smedby K, K Parsons S, Mae Rodday A, J Maurer M, M Evens A, **C El-Galaly T**, Hjort Jakobsen L. Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma. *JCO Clin Cancer Inform.* 2024 Apr;8:e2300255. doi: 10.1200/CCI.23.00255. PMID: 38608215. (IF not available)
 12. Lewis CS, Joy G, Jensen P, Barraclough A, Franco N, Talaulikar D, Hawkes EA, **El-Galaly TC**, Villa D, Dickinson M, Seymour JF, Cheah CY. Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study. *Br J Haematol.* 2024 Apr 17. doi: 10.1111/bjh.19470. Epub ahead of print. PMID: 38632873. (IF 2022:6.5)
 13. Pulczynski EJ, Simonsen MR, Kuitinen O, Fagerli UM, Erlanson M, Fluge Ø, Leppä S, Østenstad B, Fosså A, Eriksson M, **El-Galaly T**, Kuitunen H, Papworth K, Ljungqvist M, Pedersen MB, Pollari M. Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.

- Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285207. Epub ahead of print. PMID: 38546689. (IF 2022: 10.1)
14. Maksten EF, Jørgensen RRR, Pedersen MS, Fonager K, Bech RS, Mølle I, Ørskov AD, Schöllkopf C, Overgaard UM, Thomsen GN, **El-Galaly TC**, Severinsen MT. Work Disability and Return to Work After Treatment for Acute Lymphoblastic Leukemia: A Danish Nationwide Cohort Study. *Clin Epidemiol*. 2024 Mar 14;16:191-202. doi: 10.2147/CLEP.S444270. PMID: 38500516; PMCID: PMC10946445. (IF 2022: 3.9)
 15. Andersen N, Al-Mashadi AL, Rotbain EHC, Kristensen IB, Lauritsen TB, Poulsen CB, Ommen HB, Andersen CBL, **El-Galaly TC**, Abildgaard N. Treatment of the elderly patient with haematological cancer. *Ugeskr Laeger*. 2024 Jan 22;186(4):V08230538. Danish. doi: 10.61409/V08230538. PMID: 38305321.
 16. Verstovsek S, Talpaz M, Wadleigh M, Isidori A, Te Boekhorst P, Savona MR, Bose P, Pozdnyakova O, Mesa R, **El-Galaly TC**, O'Sullivan J, Gamel K, Higgins B, Katakam S, Todorov B, Trunzer K, Harrison CN. A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial. *Haematologica*. 2024 Jan 25. doi: 10.3324/haematol.2023.284410. Epub ahead of print. PMID: 38268448. (IF 2022: 10.1)

2023

17. Baech J, Husby S, Trab T, Kragholm K, Brown P, Gørløv JS, Jørgensen JM, Gudbrandsdottir S, Severinsen MT, Grønbaek K, Larsen TS, Wästerlid T, Eloranta S, Smeland KB, Jakobsen LH, **El-Galaly TC**. Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study. *Br J Haematol*. 2023 Dec 28. doi: 10.1111/bjh.19272. Epub ahead of print. PMID: 38155503. (IF 2022:6.5)
18. Jerkeman M, Kolstad A, Hutchings M, Pasanen A, Meriranta L, Niemann CU, Kragh Jørgensen RR, **El Galaly TC**, Riise J, Leppä S, Christensen JH, Sonnevi K, Pedersen LB, Wader KF, Glimelius I. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. *Blood Adv*. 2023 Dec 19;bloodadvances.2023011920. doi: 10.1182/bloodadvances.2023011920. Epub ahead of print. PMID: 38113470. (IF 2022: 7.5)
19. Wilson MR, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Lees C, Fox C, Preston G, Ahearne M, Strüßmann T, Clavert A, Rusconi C, Ku M, Khwaja J, Narkhede M, Lewis K, Durot E, Smith J, Renaud L, Ferreri AJM, **El-Galaly T**, Cwynarski K, McKay P, Eyre TA. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse. *Am J Hematol*. 2024 Feb;99(2):E46-E50. doi: 10.1002/ajh.27167. Epub 2023 Nov 30. PMID: 38037530. (IF 2021: 13.268)
20. Al-Mashhadi AL, Jakobsen LH, Brown P, Gang AO, Thorsteinsson AL, Rasoul K, Haissman JM, Tøstesen MB, Christoffersen MN, Jelacic J, Jørgensen JB, Thomsen T, Dessau-Arp A, Andersen APH, Frederiksen M, Pedersen PT, Clausen MR, Jørgensen JM, Poulsen CB, **El-Galaly TC**, Larsen TS. Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas. *Br J Haematol*. 2023 Nov 27. doi: 10.1111/bjh.19201. Epub ahead of print. PMID: 38009548. (IF 2022:6.5)
21. Maksten EF, Jakobsen LH, Modrau B, Jensvoll H, Kragholm KH, Jørgensen JM, Clausen MR, Pedersen RS, Dessau-Arp A, Larsen TS, Poulsen CB, Gang AO, Brown P, **El-Galaly TC**, Severinsen MT. Risk of dementia among older patients with lymphoma: A Danish nationwide matched cohort study. *J Geriatr Oncol*. 2023 Nov 15;15(1):101672. doi: 10.1016/j.jgo.2023.101672. Epub ahead of print. PMID: 37976653.
22. Pedersen MA, Gormsen LC, Jakobsen LH, Eyre TA, Severinsen MT, Baech J, Dann EJ, Knapp A, Sahin D, Vestergaard P, **El-Galaly TC**, Jensen P. The

- impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. *Br J Haematol.* 2023 Nov 13. doi: 10.1111/bjh.19194. Epub ahead of print. PMID: 37957542. (IF 2022:6.5)
23. Jelacic J, Juul-Jensen K, Bukumiric Z, Roost Clausen M, Ludvigsen Al-Mashhadi A, Pedersen RS, Poulsen CB, Brown P, **El-Galaly TC**, Stauffer Larsen T. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. *Blood Cancer J.* 2023 Oct 13;13(1):157. doi: 10.1038/s41408-023-00930-7. PMID: 37833260; PMCID: PMC10575851. (IF 2020: 11.037)
 24. Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, **El-Galaly TC** (§), Cheah CY; International CNS Prophylaxis Study Group. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. *J Clin Oncol.* 2023 Oct 5;JCO2300365. doi: 10.1200/JCO.23.00365. Epub ahead of print. PMID: 37797284. (IF 2021: 50.717)
 25. Trab T, Baech J, Jakobsen LH, Husby S, Severinsen MT, Eloranta S, Gørløv JS, Jørgensen JM, Gudbrandsdottir S, Larsen TS, Brown P, Grønbæk K, Smedby KE, **El-Galaly TC**. Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. *Lancet Haematol.* 2023 Oct;10(10):e838-e848. doi: 10.1016/S2352-3026(23)00212-0. Epub 2023 Sep 6. PMID: 37689081. (IF 2022: 24.7)
 26. Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Glimelius I, Marklund A, Larsen TS, Holte H, Fosså A, Smeland KB, **El-Galaly TC**, Eloranta S. Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study. *Br J Haematol.* 2023 Jun 16. doi: 10.1111/bjh.18938. Epub ahead of print. PMID: 37325886. (IF 2022:6.5)
 27. Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, Kumar A, Bond DA, Paludo J, Maurer MJ, Thanarajasingam G, Lewis KL, Cheah CY, Baech J, **El Galaly TC**, Kugathasan L, Scott DW, Gerrie AS, Lewis D. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. *Blood Adv.* 2023 Jun 12;bloodadvances.2023009804. doi: 10.1182/bloodadvances.2023009804. Epub ahead of print. PMID: 37307169. (IF 2022: 7.5)
 28. Verstovsek S, Foltz L, Gupta V, Hasserjian R, Manshouri T, Mascarenhas J, Mesa R, Pozdnyakova O, Ritchie E, Veletic I, Gamel K, Hamidi H, Han L, Higgins B, Trunzer K, Uguen M, Wang D, **El-Galaly TC**, Todorov B, Gotlib J. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. *Haematologica.* 2023 May 11. doi: 10.3324/haematol.2022.282411. Epub ahead of print. PMID: 37165840. (IF 2022: 10.1)
 29. Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Molin D, Glimelius I, Marklund A, Holte H, Fosså A, Smeland KB, **El-Galaly TC**, Eloranta S. Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study. *Int J Cancer.* 2023 Apr 29. doi: 10.1002/ijc.34552. Epub ahead of print. PMID: 37119033. (IF 2022:6.4)
 30. Lauritsen TB, Nørsgaard JM, Dalton SO, Grønbæk K, **El-Galaly TC**, Østgård LSG. 10-year nationwide trends in incidence, treatment patterns, and mortality of patients with myelodysplastic syndromes in Denmark. *Leuk Res.* 2023 Mar 10;128:107056. doi: 10.1016/j.leukres.2023.107056. Epub ahead of print. PMID: 36963210.
 31. Maksten EF, Jakobsen LH, Kragholm KH, Baech J, Andersen MP, Madsen J, Jørgensen JM, Clausen MR, Pedersen RS, Dessau-Arp A, Larsen TS, Poulsen CB, Gang AO, Brown P, Fonager K, **El-Galaly TC**, Severinsen MT. Work

- Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study. *Clin Epidemiol.* 2023 Mar 14;15:337-348. doi: 10.2147/CLEP.S399488. PMID: 36941977; PMCID: PMC10024509. (IF 2022: 3.9)
32. Kristensen DT, Øvlisen AK, Jakobsen LH, Severinsen MT, Hannig LH, Starklint J, Hilsøe MH, Vallentin AP, Brabrand M, Hasselbalch HC, **El-Galaly TC**, Roug AS. Use of statins and risk of myeloproliferative neoplasms - a Danish nationwide case-control study. *Blood Adv.* 2023 Mar 6:bloodadvances.2023009784. doi: 10.1182/bloodadvances.2023009784. Epub ahead of print. PMID: 36877642. (IF 2022: 7.5)
33. **El-Galaly TE**, Gaidzik VI, Gaman M-A, Antic D, Okosun J, Copland M, Sexl V, Fielding AK, Doeswijk R, Parker H, Dreyling M, Döhner K, Almeida AM, Macintyre E, Gribben J, Grønbaek K on behalf of the EHA Diversity, Equity, and Inclusion Taskforce. A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care. *HemaSphere* 7(3):p e842, March 2023. | DOI: 10.1097/HS9.0000000000000842. (IF 2022: 9.1)

2022

34. Ludvigsen Al-Mashhadi A, Cederleuf H, Kuhr Jensen R, Holm Nielsen T, Bjerregård Pedersen M, Bech Mortensen T, Relander T, Jerkeman M, Ortvad Gang A, Kristensen AL, Roost Clausen M, de Nully Brown P, Tang Severinsen M, Jakobsen LH, Ellin F, **El-Galaly TC** (§). Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group. *Am J Hematol.* 2023 Jan 1. doi: 10.1002/ajh.26803. Epub ahead of print. PMID: 36588403. (IF 2021: 13.268)
35. Radkiewicz C, Bruchfeld JB, Weibull CE, Jeppesen ML, Frederiksen H, Lambe M, Jakobsen L, **El-Galaly TC**, Smedby KE, Wästerlid T. Sex differences in lymphoma incidence and mortality by subtype: A population-based study. *Am J Hematol.* 2022 Sep 30. doi: 10.1002/ajh.26744. Epub ahead of print. PMID: 36178436. (IF 2020: 13.268)
36. Kristensen DT, Nielsen LB, Jakobsen LHK, Kristensen TC, Jepsen LØ, Schöllkopf C, Theilgaard-Mönch K, **El-Galaly TC**, Roug AS, Severinsen MT. Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study. *Br J Haematol.* 2022 Sep 9. doi: 10.1111/bjh.18448. Epub ahead of print. PMID: 36083781. (IF 2022:6.5)
37. Eyre TA, Savage KJ, Cheah CY, **El-Galaly TC**, Lewis KL, McKay P, Wilson MR, Evens AM, Bobillo S, Villa D, Maurer MJ, Cwynarski K, Ferreri AJM. CNS prophylaxis for diffuse large B-cell lymphoma. *Lancet Oncol.* 2022 Sep;23(9):e416-e426. doi: 10.1016/S1470-2045(22)00371-0. PMID: 36055310. (IF 2021: 54.433)
38. Jemaa S, Paulson JN, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano RAD, **El-Galaly TC**, Nielsen TG, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. *Cancer Imaging.* 2022 Aug 12;22(1):39. doi: 10.1186/s40644-022-00476-0. PMID: 35962459; PMCID: PMC9373298. (IF 2021: 5.605)
39. Wästerlid T, Murphy S, Villa D, **El-Galaly** (§). Diffuse large B-cell lymphoma among the elderly: current knowledge and future perspectives. *Ann Lymphoma* 2022 Jun 30. doi: 10.21037/aol-22-2
40. Kostakoglu L, Dalmasso F, Berchiolla P, Pierce LA, Vitolo U, Martelli M, Sehn LH, Trněný M, Nielsen TG, Bolen CR, Sahin D, Lee C, **El-Galaly TC**, Mattiello F, Kinahan PE, Chauvie S. A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA. *EJHaem.* 2022 Mar 24;3(2):406-414. doi: 10.1002/jha2.421. PMID: 35846039; PMCID: PMC9175666. (IF not available)
41. Baech J, Severinsen MT, Øvlisen AK, Frederiksen H, Vestergaard P, Torp-Pedersen C, Jørgensen JM, Clausen MR, Poulsen CB, Brown P, Gang AO,

- Pedersen R, Ekström Smedby K, Eloranta S, Hjort Jakobsen LH, **El-Galaly TC**. Risk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy. *Blood Adv*. 2022 Jun 9;bloodadvances.2021006859. doi: 10.1182/bloodadvances.2021006859. Epub ahead of print. PMID: 35679481. (IF 2022: 7.5)
42. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, **El-Galaly TC**, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. *Lancet Haematol*. 2022 May;9(5):e374-e384. doi: 10.1016/S2352-3026(22)00045-X. PMID: 35483398. (IF 2022: 24.7)
43. Harrysson S, Eloranta S, Ekberg S, Enblad G, **El-Galaly TC**, Sander B, Sonnevi K, Andersson PO, Jerkeman M, Smedby KE. Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients. *Br J Haematol*. 2022 Apr 25. doi: 10.1111/bjh.18197. Epub ahead of print. PMID: 35468219. (IF 2022:6.5)
44. **El-Galaly TC**, Glimelius I. Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack? *Br J Haematol*. 2022 Apr 19. doi: 10.1111/bjh.18199. Epub ahead of print. PMID: 35438825. (IF 2022:6.5)
45. Juul MB, Jelacic J, Anru PL, Engberg H, Hammershøj Jensen P, Kristensen HB, Baech J, Clausen MR, Gang AO, Munksgaard L, **El-Galaly TC**, Frederiksen H, Stauffer Larsen T. Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study. *Leuk Lymphoma*. 2022 Apr 18:1-10. doi: 10.1080/10428194.2022.2064982. Epub ahead of print. PMID: 35437098. (IF 2020: 3.28)
46. Øvlisen AK, Jakobsen LH, Kragholm KH, Nielsen RE, de Nully Brown P, Dahl-Sørensen RB, Frederiksen H, Mannering N, Josefsson PL, Ludvigsen Al-Mashhadi A, Jørgensen JM, Dessau-Arp A, Clausen MR, Pedersen RS, Torp-Pedersen C, Severinsen MT, **El-Galaly TC**. Mental Health Among Patients with non-Hodgkin Lymphoma: a Danish Nationwide Study of Psychotropic Drug Use in 8,750 Patients and 43,750 Matched Comparators. *Am J Hematol*. 2022 Jun 1;97(6):749-761. doi: 10.1002/ajh.26538. Epub 2022 Mar 29. PMID: 35298039. (IF 2021:13.268)
47. Jensen O, Øvlisen AK, Jakobsen LH, Roug AS, Nielsen RE, Marcher CW, Ebbesen LH, Theilgaard-Mönch K, Møller P, Schöllkopf C, Torp-Pedersen C, **El-Galaly TC**, Severinsen MT. Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients. *Clin Epidemiol*. 2022 Feb 25;14:225-237. doi: 10.2147/CLEP.S336115. PMID: 35241936; PMCID: PMC8887140. (IF 2022: 3.9)
48. Eyre TA, Jensen P, Booth S, **El-Galaly TC**. Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures. *Br J Haematol*. 2022 Mar 2. doi: 10.1111/bjh.18104. Epub ahead of print. PMID: 35235226. (IF 2022:6.5)
49. Husby S, Jørgensen GØ, Favero F, Jespersen JS, Rodriguez-Gonzalez FG, Nielsen C, Sorensen B, Ebbesen LH, Bæch J, Haastrup EK, Josefsson P, Thorsgaard M, Brown P, **El-Galaly TC**, Larsen TS, Weischenfeldt J, Grønbaek K. Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT. *Bone Marrow Transplant*. 2022 Feb 5. doi: 10.1038/s41409-022-01580-2. Epub ahead of print. PMID: 35124694. (IF 2020: 5.483)

50. Jakobsen LH, Øvlisen AK, Severinsen MT, Bæch J, Kragholm KH, Glimelius I, Gang AO, Jørgensen JM, Frederiksen H, Poulsen CB, Clausen MR, Pedersen PT, Pedersen RS, Torp-Pedersen C, Eloranta S, **El-Galaly TC**. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. *Blood Cancer J*. 2022 Jan 27;12(1):16. doi: 10.1038/s41408-022-00614-8. PMID: 35087026. (IF 2020: 11.037)
51. Jensen P, Hjort Jakobsen LH, Bøgsted M, Bæch J, Lykkeboe S, Severinsen MT, Vestergaard P, **El-Galaly TC**. A randomised trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment. *Blood Adv*. 2022 Apr 26;6(8):2549-2556. doi: 10.1182/bloodadvances.2021006330. PMID: 35045567; PMCID: PMC9043936. (IF 2022: 7.5)
52. Harris W, Bataillard EJ, Choi Y, **El-Galaly TC**, Cuchelkar V, Hennes C, Kwan A, Schneider DJ, Paulson JN, Nielsen TG. TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma. *JCO Clin Cancer Inform*. 2022 Jan;6:e2100121. doi: 10.1200/CCI.21.00121. PMID: 35044836. (IF not available)
53. Joelsson JK, Wåsterlid T, Rosenquist R, Hjort Jakobsen LH, **El-Galaly TC**, Ekström Smedby K, Eloranta S. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. *Blood Adv*. 2022 Apr 26;6(8):2657-2666. doi: 10.1182/bloodadvances.2021006369. PMID: 35042239; PMCID: PMC9043935. (IF 2022: 7.5)
54. Mascarenhas J, Passamonti F, Burbury K, **El-Galaly TC**, Gerds AT, Gupta V, Higgins B, Wonde K, Jamois C, Kovic B, Huw LY, Katakam S, Maffioli M, Mesa RA, Palmer JM, Bellini M, Ross DM, Vannucchi AM, Yacoub A. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. *Blood Adv*. 2022 Feb 22;6(4):1162-1174. doi: 10.1182/bloodadvances.2021006043. PMID: 34933330; PMCID: PMC8864654.. (IF 2022: 7.5)
55. **El-Galaly TC**, Villa D, Cheah CY, Gormsen LC. Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter? *Br J Haematol*. 2022 Apr;197(2):139-155. doi: 10.1111/bjh.18016. Epub 2022 Jan 17. PMID: 35037240. (IF 2022:6.5)
56. Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne MJ, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, Mcilroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüessmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, **El Galaly TC**, Ferreri AJM, Cwynarski K, McKay P. Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients. *Blood*. 2022 Apr 21;139(16):2499-2511. doi: 10.1182/blood.2021014506. PMID: 34995350. (IF 2020: 23.629)

2021

57. Shanmuganathan JWD, Kragholm K, Tayal B, Polcwiartek C, Poulsen LØ, **El-Galaly TC**, Fosbøl EL, D'Souza M, Gislason G, Køber L, Schou M, Nielsen D, Sjøgaard P, Torp-Pedersen CT, Mamas MA, Freeman P. Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer: A Nationwide Registry-Based Study. *JACC CardioOncol*. 2021 Dec 21;3(5):725-733. doi: 10.1016/j.jacc.2021.11.001. PMID: 34988482; PMCID: PMC8702810. (IF 2020: 6.25)
58. Barrington SF, Mir F, **El-Galaly TC**, Knapp A, Nielsen TG, Sahin D, Wenger M, Kostakoglu L, Trotman J, Meignan M. Follicular lymphoma treated with

- first-line immunochemotherapy: a review of PET-CT in patients who did not achieve CMR in the GALLIUM study. *J Nucl Med*. 2021 Dec 2;jnumed.121.262869. doi: 10.2967/jnumed.121.262869. Epub ahead of print. PMID: 34857656. (IF 2020: 10.057)
59. Sommer M, Nielsen LK, Nielsen LB, Brøndum RF, Nielsen MM, Rytter AS, Vesteghem C, Severinsen MT, **El-Galaly TC**, Bøgsted M, Grønkjær M, Jørgensen L. Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study. *Health Qual Life Outcomes*. 2021 Nov 4;19(1):251. doi: 10.1186/s12955-021-01887-6. PMID: 34736479; PMCID: PMC8567661. (IF 2020: 3.186)
 60. **El-Galaly TC**, Øvlisen AK, Cheah CY. Routine imaging for disease surveillance in follicular lymphoma-To comfort the patients or their doctors? *Cancer*. 2021 Sep 15;127(18):3298-3301. doi: 10.1002/cncr.33659. Epub 2021 Jun 22. PMID:34157785. (IF 2021: 6.921)
 61. Brøndum RF, Vestergaard AS, Børty L, Vesteghem C, Rytter AS, Nielsen MM, Severinsen MT, Jensen P, Gregersen H, **El-Galaly TC**, Dybkær K, Ehlers LH, Bøgsted M, Roug AS. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. *Future Oncol*. 2021 Sep;17(25):3331-3341. doi: 10.2217/fo-2021-0189. Epub 2021 Jun 22. PMID: 34156281.(IF 2020: 3.404)
 62. Nestic M, Sønderkær M, Brøndum RF, **El-Galaly TC**, Pedersen IS, Bøgsted M, Dybkær K. The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. *BMC Cancer*. 2021 Jul 18;21(1):829. doi: 10.1186/s12885-021-08556-3. PMID: 34275438; PMCID: PMC8286604. (IF 2020: 4.43)
 63. Øvlisen AK, Jakobsen LH, Elontra S, Kragholm K, Hutchings M, Frederiksen H, Kamper P, Dahl-Sørensen RB, Stoltenberg D, Weibull CE Entrop JP, Glimelius I, Smedby KE, Torp-Pedersen D, Severinsen MT, **El-Galaly TC** (§). Parenthood rates and use of assisted reproduction techniques in younger Hodgkin lymphoma survivors: A Danish population-based study of 793 patients and 3,965 matched comparators. *J Clin Oncol*. 2021 Nov 1;39(31):3463-3472. doi:10.1200/JCO.21.00357. Epub 2021 Jun 25. PMID: 34170749. (IF 2021: 50.717)
 64. Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, **El-Galaly TC**. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. *Blood Adv*. 2021 May 11;5(9):2426-2437. doi: 10.1182/bloodadvances.2021004665. PMID: 33961018. (IF 2022: 7.5)
 65. Naur TMH, Jakobsen LH, Roug AS, **El-Galaly TC**, Marcher CW, Nørgaard JM, Theilgaard-Mönch K, Møller P, Schöllkopf C, Severinsen MT. Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001-2016: a Danish nationwide cohort study. *Leuk Lymphoma*. 2021 Mar 12:1-4. doi: 10.1080/10428194.2021.1893315. Epub ahead of print. PMID: 33711911. (IF 2020: 3.28)
 66. Maurer MJ, Jakobsen LH, Mwangi R, Schmitz N, Farooq U, Flowers CR, de Nully Brown P, Thompson CA, Frederiksen H, Cunningham D, Jørgensen J, Poeschel V, Nowakowski G, Seymour JF, Merli F, Haioun C, Ghesquieres H, Ziepert M, Tilly H, Salles G, Shi Q, **El-Galaly TC**, Habermann TM. R/R International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. *Am J Hematol*. 2021 Mar 4. doi: 10.1002/ajh.26149. Epub ahead of print. PMID: 33661547. (IF 2021:13.268)
 67. Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf

- Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, **El-Galaly TC**, Evens AM. Burkitt Lymphoma International Prognostic Index. *J Clin Oncol*. 2021 Jan 27;JCO2003288. doi: 10.1200/JCO.20.03288. Epub ahead of print. PMID: 33502927. (IF 2021: 50.717)
68. Jakobsen LH, Callréus T, Sessa M, Jerkeman M, Andersen M, **El-Galaly TC**. Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma. *Pharmacoepidemiol Drug Saf*. 2021 Jan 12. doi: 10.1002/pds.5195. Epub ahead of print. PMID: 33432654. (IF 2020: 2.89)
69. Sommer M, Frandsen L, Jensen P, Bøgstед M, **El-Galaly TC**, Grønkjær M. Hematological cancer survivors' experiences of participating in a shared care follow-up-an exploratory interview study. *J Cancer Surviv*. 2021 Jan 6. doi: 10.1007/s11764-020-00955-y. Epub ahead of print. PMID: 33405058. (IF 2020: 4.442)

2020

70. Wästerlid T, Oren Gradel K, Eloranta S, Glimelius I, **El-Galaly TC**, Frederiksen H, Smedby KE. Clinical characteristics and outcomes among 2347 patients aged ≥ 85 years with major lymphoma subtypes: a Nordic Lymphoma Group study. *Br J Haematol*. 2020 Nov 24. doi: 10.1111/bjh.17250. Epub ahead of print. PMID: 33236363. (IF 2022:6.5)
71. Hjort Jakobsen L, Stidsholt Roug A, Kiesbye Øvlisen A, Werenberg Marcher C, Beier Ommen H, Theilgaard-Mönch K, Møller P, Schöllkopf C, Kristensen D, Maria Henriette Naur T, Bøgstед M, **Christoffer El-Galaly T**, Tang Severinsen M. Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study. *Br J Haematol*. 2020 Nov 21. doi: 10.1111/bjh.17213. Epub ahead of print. PMID: 33222154. (IF 2022:6.5)
72. Sommer M, Frandsen L, Jensen P, Nielsen SR, Nielsen LB, Brøndum RF, Bøgstед M, Madsen J, Severinsen MT, Sørensen EE, Grønkjær M, **El-Galaly TC**. Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region. *BMC Health Serv Res*. 2020 Nov 17;20(1):1047. doi: 10.1186/s12913-020-05899-8. PMID: 33198756; PMCID: PMC7670769. (IF 2020: 2.655)
73. Jakobsen LH, Øvlisen AK, Eloranta S, Bøgstед M, Severinsen MT, Smedby KE, Maurer MJ, **El-Galaly TC**. A narrative review of survival normalization in non-Hodgkin lymphoma: useful for better patient counselling and an endpoint for clinical trials? *Ann Lymphoma* 2020;4:5 (IF not available)
74. Schönherz AA, Bødker JS, Schmitz A, Brøndum RF, Jakobsen LH, Roug AS, Severinsen MT, **El-Galaly TC**, Jensen P, Johnsen HE, Bøgstед M, Dybkær K. Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. *PLoS One*. 2020 Apr 23;15(4):e0229593. doi: 10.1371/journal.pone.0229593. eCollection 2020. PubMed PMID: 32324791. (IF 2020: 3.24)
75. Kristensen D, Nielsen LB, Roug AS, Kristensen TC, **El-Galaly TC**, Nørgaard JM, Marcher CW, Schöllkopf C, Theilgaard-Mönch K, Severinsen MT. The prognostic effect of smoking status on intensively treated acute myeloid leukaemia – A Danish nationwide cohort study. *Br J Haematol*. 2020 Apr 21. doi: 10.1111/bjh.16667. [Epub ahead of print] PubMed PMID: 32316076. (IF 2022:6.5)
76. Øvlisen AK, Jakobsen LH, Kragholm KH, Nielsen RE, Hutchings M, Dahl-Sørensen RB, Frederiksen H, Stoltenberg D, Bøgstед M, Østgård LSG, Severinsen MT, **El-Galaly TE (§)**. Depression and Anxiety in Hodgkin Lymphoma Patients: a Danish Nationwide Cohort Study of 896 Patients. *Cancer*

- Med. 2020 Apr 17. doi: 10.1002/cam4.2981. [Epub ahead of print] PubMed PMID: 32301251. (§ Shared last authorship). (IF 2020: 4.452)
77. Nestic M, **El-Galaly TC**, Bøgsted M, Pedersen IS, Dybkær K. Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. *Expert Rev Hematol*. 2020 Apr 15. doi: 10.1080/17474086.2020.1755958. [Epub ahead of print] PubMed PMID: 32293210. (IF 2020: 2.929)
78. Jakobsen LH, Andersson TM-L, Bicler JL, Poulsen LØ, Severinsen MT, **El-Galaly TC**, Bøgsted M. On Estimating the Time to Statistical Cure. *BMC Med Res Methodol*. 2020 Mar 26;20(1):71. doi: 10.1186/s12874-020-00946-8. PubMed PMID: 32216765; PubMed Central PMCID: PMC7098130. (IF 2020: 4.615)
79. Husby S, Favero F, Nielsen C, Sørensen BS, Bæch J, Grell K, Hansen JW, Rodriguez-Gonzalez FG, Haastrup EK, Fischer-Nielsen A, Andersen P, Arboe B, Sækmoose SG, Hansen PB, Christiansen I, Clasen-Linde E, Meldgaard L, Ebbesen LH, Segel EK, Josefsson P, Thorsgaard M, **El-Galaly TC**, Brown P, Weischenfeldt J, Larsen TS, Grønbæk K. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. *Leukemia*. 2020 Mar 20. doi: 10.1038/s41375-020-0795-z. [Epub ahead of print] PubMed PMID:32203146. (IF 2020: 11.528)
80. **El-Galaly TC**, Cheah CY, Kristensen D, Hutchison A, Hay K, Callréus T, Villa D. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. *Acta Oncol*. 2020 Mar 19:1-9. doi: 10.1080/0284186X.2020.1741680. [Epub ahead of print] PubMed PMID: 32189546. (IF 2020: 4.089)
81. Morello L, Rattotti S, Giordano L, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, Ferrero S, Szymczyk M, Aurer I, **El-Galaly TC**, Di Rocco A, Visco C, Carli G, Defrancesco I, Carlo-Stella C, Dreyling M, Santoro A, Arcaini L. Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. *Hemasphere*. 2019 Dec 16;4(1):e302. doi: 10.1097/HS9.0000000000000302. eCollection 2020 Feb. PubMed PMID: 32072136; PubMed Central PMCID: PMC7000480. (IF not available)
82. Bæch J, Hansen SM, Jakobsen LH, Øvlisen AK, Severinsen MT, Brown PN, Vestergaard P, Frederiksen H, Jørgensen J, Starklint J, Josefsson P, Hammer T, Clausen MR, Torp-Pedersen C, Jensen P, **El-Galaly TC**. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. *Leuk Lymphoma*. 2020 Feb 11:1-10. doi: 10.1080/10428194.2020.1723015. [Epub ahead of print] PubMed PMID: 32043382. (IF 2020: 3.28)
83. Jakobsen LH, Ellin F, Smeland KB, Wæsterlid T, Christensen JH, Jørgensen JM, Josefsson PL, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, **El-Galaly TC**. Minimal relapse risk and excellent survival among Burkitt lymphoma patients treated with intensive immunochemotherapy. *Br J Haematol*. 2020 Feb 4. doi: 10.1111/bjh.16425. [Epub ahead of print] PubMed PMID: 32017050. (IF 2022:6.5)
84. Bødker JS, Sønderkær M, Vesteghem C, Schmitz A, Brøndum RF, Sommer M, Rytter AS, Nielsen MM, Madsen J, Jensen P, Pedersen IS, Grubach L, Severinsen MT, Roug AS, **El-Galaly TC**, Dybkær K, Bøgsted M. Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. *Cancers (Basel)*. 2020 Jan 29;12(2). pii: E312. doi: 10.3390/cancers12020312. PubMed PMID: 32013121. (IF 2020: 6.39)
85. **El-Galaly TC**, Cheah CY. Mantle cell lymphoma – where precision medicine based on response-adapted treatment strategies could show its full worth. *Br J Haematol*. 2020 Jan 30. doi: 10.1111/bjh.16396. [Epub ahead of print] PubMed PMID: 31997341. (IF 2022:6.5)
86. Sunderland AJ, Steiner RE, Al Zahrani M, Pinnix CC, Dabaja BS, Gunther JR,

Nastoupil LJ, Jerkeman M, Joske D, Cull G, **El-Galaly T**, Villa D, Cheah CY. An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. *Cancer Med.* 2020 Jan;9(2):663-670. doi: 10.1002/cam4.2732. Epub 2019 Dec 5. PubMed PMID: 31808316; PubMed Central PMCID: PMC6970027. (IF 2020: 4.452)

2019

87. Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, **El-Galaly T**, Villa D, Cheah CY. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. *Blood Adv.* 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251. PubMed PMID: 31285189; PubMed Central PMCID: PMC6616265. (IF 2022: 7.5)
88. Vesteghem C, Brøndum RF, Sønderkær M, Sommer M, Schmitz A, Bødker JS, Dybkær K, **El-Galaly TC**, Bøgsted M. Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives. *Brief Bioinform.* 2019 Jun 29. pii: bbz044. doi: 10.1093/bib/bbz044. [Epub ahead of print] PubMed PMID: 31263868. (IF 2020: 11.622)
89. Pálmarsdóttir R, Kiesbye Øvlisen A, Severinsen MT, Glimelius I, Smedby KE, **El-Galaly T**. Socioeconomic impact of Hodgkin lymphoma in young adults: a systematic literature review. *Leuk Lymphoma.* 2019 Jun 6:1-16. doi: 10.1080/10428194.2019.1613538. [Epub ahead of print] PubMed PMID: 31167589. (IF 2020: 3.28)
90. **El-Galaly TC**, Cheah CY, Villa D. Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. *Br J Haematol.* 2019 May 29. doi: 10.1111/bjh.15965. [Epub ahead of print] Review. PubMed PMID: 31140600. (IF 2022:6.5)
91. Jakobsen LH, Biccler JL, Brown PN, Jørgensen JM, Josefsson PL, Poulsen CB, Starklint J, Clausen MR, Pedersen PT, Juul MB, Severinsen MT, Bøgsted M, **El-Galaly TC**. No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients. *Leuk Lymphoma.* 2019 May 6:1-4. doi: 10.1080/10428194.2019.1602264. [Epub ahead of print] PubMed PMID: 31057011. (IF 2020: 3.28)
92. Gormsen LC, Vendelbo MH, Pedersen MA, Haraldsen A, Hjorthaug K, Bogsrud TV, Petersen LJ, Jensen KJ, Brøndum R, **El-Galaly TC**. A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT. *EJNMMI Res.* 2019 May 3;9(1):36. doi: 10.1186/s13550-019-0503-z. PubMed PMID: 31054023. (IF 2020: 3.138)
93. Callréus T, **El-Galaly TC**, Jerkeman M, de Nully Brown P, Andersen M. Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. *Pharmaceut Med.* 2019 Apr;33(2):83-88. doi: 10.1007/s40290-019-00270-7. PubMed PMID: 31933251. (IF not available)
94. Biccler JL, Savage KJ, Brown PDN, Jørgensen J, Larsen TS, Poulsen CB, Stoltenberg D, Sehn LH, Scott DW, Gerrie AS, Jakobsen LH, Bøgsted M, **El-Galaly TC** (§), Villa D. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. *Leuk Lymphoma.* 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594219. [Epub ahead of print] PubMed PMID: 30943052. (IF 2020: 3.28)
95. Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova YM, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, **El-Galaly TC**, Hodgson DC, Ricardi U, Yahalom J, Mikhael NG, Hoppe RT. Salvage

Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. *Int J Radiat Oncol Biol Phys.* 2019 Mar 8. pii: S0360-3016(19)30317-7. doi: 10.1016/j.ijrobp.2019.03.004. [Epub ahead of print] PubMed PMID: 30858143. (IF 2020: 7.038)

96. Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown PN, Jakobsen LH, Frederiksen H, Jerkeman M, Fosså A, Andersson TML, Holte H, Bøgsted M, **El-Galaly TC** (§), Smedby KE. Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. *J Clin Oncol.* 2019 Feb 6;JCO1801652. doi: 10.1200/JCO.18.01652. [Epub ahead of print] [PubMed PMID: 30726176](#). (IF 2021: 50.717)
97. Jakobsen LH, Andersson TM, Biccler JL, **El-Galaly TC**, Bøgsted M. Estimating the loss of lifetime function using flexible parametric relative survival models. *BMC Med Res Methodol.* 2019 Jan 28;19(1):23. doi: 10.1186/s12874-019-0661-8. PubMed PMID: 30691400. (IF 2020: 4.615)
98. Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Krog Vistisen A, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, **El-Galaly TC**, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhael NG. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. *Blood.* 2019 Jan 17;133(3):237-245. doi: 10.1182/blood-2018-04-843540. Epub 2018 Nov 16. PubMed PMID: 30446493. (IF 2020: 23.629)

2018

99. Biccler J, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Jørgensen J, Johnsen HE, Jakobsen LH, Smedby KE, Bøgsted M, **El-Galaly TE**. Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by use of Machine Learning and Nationwide Lymphoma Registries: a Nordic Lymphoma Group Study. *JCO Clin Cancer Inform.* 2018 Dec;2:1-13. doi: 10.1200/CCI.18.00025. PubMed PMID: 30652603. (IF not available)
100. Nørgaard CH, Søgaaard NB, Biccler JL, Pilgaard L, Eskesen MH, Kjartansdottir TH, Bøgsted M, **El-Galaly TC**. Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study. *PLoS One.* 2018 Dec 27;13(12):e0208180. doi: 10.1371/journal.pone.0208180. eCollection 2018. PubMed PMID: 30589850; PubMed Central PMCID: PMC6307783. (IF 2020: 3.24)
101. Biccler JL, **El-Galaly TC**, Bøgsted M, Jørgensen J, de Nully Brown P, Poulsen CB, Starklint J, Juul MB, Christensen JH, Josefsson P, Dessau A, Jakobsen LH. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas. *Leuk Lymphoma.* 2018 Nov 14:1-4. doi:10.1080/10428194.2018.1540044. [Epub ahead of print] PubMed PMID: 30424711. (IF 2020: 3.28)
102. Baech J, Hansen SM, Lund PE, Soegaard P, Brown PN, Jørgensen J, Starklint J, Josefsson P, Poulsen CB, Juul MB, Torp-Pedersen C, **El-Galaly TE**. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. *Br J Haematol* 2018 Nov 8. doi: 10.1111/bjh.15603. [Epub ahead of print] PubMed PMID: 30406945. (IF 2022: 6.5)
103. Bødker JS, Brøndum RF, Schmitz A, Schönherz AA, Jespersen DS, Sønderkær M, Vesteghem C, Due H, Nørgaard CH, Perez-Andres M, Samur MK, Davies F, Walker B, Pawlyn C, Kaiser M, Johnson D, Bertsch U, Broyl A, van Duin M, Shah R, Johansen P, Nørgaard MA, Samworth RJ, Sonneveld P, Goldschmidt H, Morgan GJ, Orfao A, Munshi N, Johnson HE, **El-Galaly T**, Dybkær K, Bøgsted M. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. *Blood Adv.* 2018 Sep 25;2(18):2400-2411.

doi: 10.1182/bloodadvances.2018018564. PubMed PMID: 30254104; PubMed Central PMCID: PMC6156884. (IF 2022: 7.5)

104. **El-Galaly TE**, Villa D, Gormsen LC, Baech J, Lo A, Cheah Cy. FDG-PET/CT in the management of lymphomas: current status and future directions. *J Intern Med*. 2018 Jul 10. doi: 10.1111/joim.12813. [Epub ahead of print] Review. PubMed PMID: 29989234. (IF 2020: 8.989)
105. Juul MB, Jensen PH, Engberg H, Wehberg S, Dessau-Arp A, Haziri D, Kristensen HB, Baech J, Schurmann L, Clausen MR, Valentin R, Knudsen LM, Munksgaard L, **El-Galaly TC**, Frederiksen H, Larsen TS. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. *Eur J Cancer*. 2018 Aug;99:86-96. doi: 10.1016/j.ejca.2018.05.006. Epub 2018 Jun 20. PubMed PMID: 29935491. (IF 2020: 9.162)
106. Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, **El-Galaly TC**, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. *Lancet Haematol*. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review. PubMed PMID: 29907552 (IF 2022: 24.7)
107. Wästerlid T, Biccler JL, Brown PdN, Bøgsted M, Enblad G, Jørgensen JM, Christensen JH, Wahlin BE, Smedby KE, **El-Galaly TC**, Jerkeman M. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma - A Nordic Lymphoma Group population-based study. *Ann Oncol*. 2018 Aug 1;29(8):1882-1883. doi: 10.1093/annonc/mdy184. PubMed PMID: 29790897. (IF 2020: 32.976)
108. Chin CK, Tsang E, Mediwake H, Khair W, Biccler J, Hapgood G, Mollee P, Nizich Z, Joske D, Radeski D, Cull G, Villa D, **El-Galaly TC**, Cheah CY. Frequency of bowel perforation and impact of bowel rest in aggressive non Hodgkin's lymphoma with gastrointestinal involvement. *Br J Haematol*. 2018 Apr 20. doi: 10.1111/bjh.15173. [Epub ahead of print] PubMed PMID: 29676487. (IF 2022: 6.5)
109. Sørensen N, Jensen P, Clasen-Linde E, Larsen JM, **El-Galaly T**. Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP. *Clin Case Rep*. 2018 Jan 26;6(3):490-493. doi: 10.1002/ccr3.1390. eCollection 2018 Mar. PubMed PMID: 29531724; PubMed Central PMCID: PMC5838273. (IF not available)
110. Nørgaard CH, Jakobsen LH, Gentles AJ, Dybkær K, **El-Galaly TC**, Bødker JS, Schmitz A, Johansen P, Herold T, Spiekermann K, Brown JR, Klitgaard JL, Johnsen HE, Bøgsted M. Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. *PLoS One*. 2018 Mar 7;13(3):e0193249. doi: 10.1371/journal.pone.0193249. eCollection 2018. (IF 2020: 3.24)
111. **El-Galaly TE**, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Cecchetti C, Farooq U, Link BK, Ferreri AJM, Calimeri T, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. Treatment Strategies, Outcomes, and Prognostic Factors in 291 Patients with Secondary CNS Involvement by Diffuse Large B-Cell Lymphoma. *Eur J Cancer*. 2018 Feb 21;93:57-68. doi: 10.1016/j.ejca.2018.01.073. [Epub ahead of print] PubMed PMID: 29477102. (IF 2020: 9.162)

112. Biccler JL, Østgård LSG, Severinsen MT, Marcher CW, Møller P, Schöllkopf C, Friis LS, Bøgsted M, Jakobsen LH, **El-Galaly TC** (§), Nørgaard JM. Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study. *Leukemia*. 2018 Oct;32(10):2263-2303. doi: 10.1038/s41375-018-0054-8. Epub 2018 Feb 23. PubMed PMID: 29476132. (IF 2020: 11.528)
113. Biccler J, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Smedby KE, Bøgsted M, **El-Galaly TC**. Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. *Cancer Med*. 2017 Dec 13. doi: 10.1002/cam4.1271. [Epub ahead of print] PubMed PMID: 29239133. (IF 2020: 4.452)
114. **El-Galaly TC**, Gormsen LC, Hutching M, PET/CT for Staging: Past, Present, and Future. *Semin Nucl Med*. 2018 Jan;48(1):4-16. doi:10.1053/j.semnuclmed.2017.09.001. Epub 2017 Sep 21. Review. PubMed PMID:29195617. (IF 2020: 4.446)
115. Cottreau AS, **El-Galaly TC**, Becker S, Broussais F, Peterson LJ, Bonnet C, Prior JO, Tilly H, Hutchings M, Casasnovas O, Meignan MA. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients. *J Nucl Med*. 2018 Apr;59(4):589-595. doi: 10.2967/jnumed.117.193946. Epub 2017 Sep 1. PubMed PMID: 28864629. (IF 2020: 10.057)
116. **El-Galaly TC**, Cheah CY. Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. *Leuk Lymphoma*. 2018 Apr;59(4):775-777. doi: 10.1080/10428194.2017.1365863. Epub 2017 Aug 22. PubMed PMID: 28828884. (IF 2020: 3.28)
117. Bech RS, Nielsen KL, Larsen TS, Bentzen HH, Lynggaard LS, Do TH, Braendstrup P, Brady J, Mikhaeel NG, Dybkaer K, Johnsen HE, Jensen P, Bøgsted M, **El-Galaly TC**. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma. *Br J Haematol*. 2017 May 23. doi: 10.1111/bjh.14775. [Epub ahead of print] PubMed PMID: 28542714. (IF 2022: 6.5)

2017

118. Cederleuf H, Hjort Jakobsen L, Ellin F, de Nully Brown P, Stauffer Larsen T, Bøgsted M, Relander T, Jerkeman M, **El-Galaly TC**. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. *Leuk Lymphoma*. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1300888. [Epub ahead of print] PubMed PMID: 28317459. (IF 2020: 3.28)
119. **El-Galaly TC**, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Johnsen HE, Seymour JF, Connors JM, Brown Pd, Bøgsted M, Cheah CY. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multi-center study of 1532 patients treated with chemoimmunotherapy. *Eur J Cancer*. 2017 Feb 23. doi: 10.1016/ejca.2016.12.029 [Epub ahead of print] PubMed PMID: 28237865. (IF 2020: 9.162)
120. Zwarthoed C, **El-Galaly TC**, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, Viviani S, Rigacci L, Trentin L, Rusconi C, Luminari S, Cantonetti M, Bolis S, Borra A, Darcourt J, Salvi F, Subocz E, Tajer J, Kulikowski W, Malkowski B, Zaucha JM, Gallamini A. Prognostic value of bone marrow tracer uptake pattern in baseline PET scan in Hodgkin Lymphoma: results from an International Collaborative Study. *J Nucl Med*. 2017 Jan 26. pii: jnumed.116.184218. doi: 10.2967/jnumed.116.184218. [Epub ahead of print] PubMed PMID: 28126883. (IF 2020: 10.057)
121. Bødker JS, Severinsen MT, **El-Galaly TC**, Brøndum RF, Laursen MB, Falgreen S, Nyegaard M, Schmitz A, Jakobsen LH, Schönherz AA, Due H, Reinholdt L,

Bøgsted M, Dybkær K, Johnsen HE. Molecular classification of tissue from a transformed non-Hodgkin's lymphoma case with unexpected long-time remission. *Exp Hematol Oncol*. 2017 Jan 11;6:3. doi: 10.1186/s40164-016-0063-0. PubMed PMID: 28097046; PubMed Central PMCID: PMC5225590. (IF 2020: 5.133)

122. Jakobsen LH, Bøgsted M, Brown PN, Arboe B, Jørgensen J, Larsen TS, Juul MB, Schurmann L, Højberg L, Bergmann OJ, Lassen T, Josefsson PL, Jensen P, Johnsen HE, **El-Galaly TC**. Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. *J Clin Oncol*. 2017 Jan 17;JCO2016700765. doi: 10.1200/JCO.2016.70.0765. [Epub ahead of print] PubMed PMID: 28095160. (IF 2021: 50.717)

2016

123. Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, **El-Galaly TC**, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K. The myeloma stem cell concept, revisited: from phenomenology to operational terms. *Haematologica*. 2016 Dec;101(12):1451-1459. Review. PubMed PMID: 27903712 (IF 2022: 10.1)
124. Bendtsen MD, Munksgaard PS, Severinsen MT, Bekric E, Brieghel C, Nielsen KB, de Nully Brown P, Dybkær K, Johnsen HE, Bøgsted M, **El-Galaly TC**. Anthropometrics and Prognosis in Diffuse Large B-Cell Lymphoma: A Multicentre Study of 653 Patients. *Eur J Haematol*. 2016 Nov 28. doi: 10.1111/ejh.12835 (IF 2020: 2.997)
125. Svendsen P, Shekhrayka N, Nielsen KL, Vestergaard P, Poulsen MØ, Vistisen AK, Munksgaard PS, Severinsen MT, Jensen P, Johnsen HE, Jakobsen LH, Bøgsted M, Frøkjær JB, **El-Galaly TC**. *Leuk Lymphoma*. 2016 Oct 13:1-9. PMID: 27736260 (IF 2020: 3.28)
126. Falgreen S, Ellern Bilgrau A, Brøndum RF, Hjort Jakobsen L, Have J, Lindblad Nielsen K, **El-Galaly TC**, Bødker JS, Schmitz A, H Young K, Johnsen HE, Dybkær K, Bøgsted M. hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. *PLoS One*. 2016 Oct 4;11(10):e0163711. doi: 10.1371/journal.pone.0163711. PubMed PMID: 27701436; PubMed Central PMCID: PMC5049784. (IF 2020: 3.24)
127. **El-Galaly TC**, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Poulsen MØ, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Bøgsted M, Johnsen HE, Seymour JF, Connors JM, Brown PD, Villa D. [Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement](#). *Br J Haematol*. 2016 Sep 29. doi: 10.1111/bjh.14325. (IF 2022: 6.5)
128. Arboe B, **El-Galaly TC**, Clausen MR, Munksgaard PS, Stoltenberg D, Nygaard MK, Klausen TW, Christensen JH, Gørløv JS, Brown Pde N. The Danish National Lymphoma Registry: Coverage and Data Quality. *PLoS One*. 2016 Jun 23;11(6):e0157999. doi: 10.1371/journal.pone.0157999. PubMed PMID: 27336800; PubMed Central PMCID: PMC4919044. (IF 2020: 3.24)
129. Bergkvist KS, Nørgaard MA, Bøgsted M, Schmitz A, Nyegaard M, Gaihede M, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Urup T, **El-Galaly TC**, Madsen J, Bødker JS, Dybkær K, Johnsen HE. Characterization of memory B cells from thymus and its impact for DLBCL classification. *Exp Hematol*. 2016 Oct;44(10):982-990.e11. doi: 10.1016/j.exphem.2016.06.001. PubMed PMID: 27297329. (IF 2020: 5.133)
130. Due H, Svendsen P, Bødker JS, Schmitz A, Bøgsted M, Johnsen HE, **El-Galaly TC**, Roug AS, Dybkær K. miR-155 as a Biomarker in B-Cell Malignancies. *Biomed Res Int*. 2016;2016:9513037. doi: 10.1155/2016/9513037. Review.

PubMed PMID: 27294145; PubMed Central PMCID: PMC4884835. (IF 2020: 3.411)

131. Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, **El-Galaly TC**, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. *Am J Hematol*. 2016 Sep;91(9):894-9. doi: 10.1002/ajh.24429. PubMed PMID: 27222367. (IF 2021:13.268)
132. Alzahrani M, **El-Galaly TC**#, Hutchings M, Hansen JW, Loft A, Johnsen HE, Iyer V, Wilson D, Sehn LH, Savage KJ, Connors JM, Gascoyne RD, Johansen P, Clasen-Linde E, Brown P, Villa D. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. *Ann Oncol*. 2016 Mar 21. pii: mdw137. [Epub ahead of print] PMID: 27002106 (IF 2020: 32.976)
133. Johnsen HE, **El-Galaly TC**, Dybkær K, Bøgsted M. Blood on the tracks – toward precision medicine. *Leuk Lymphoma*. 2016 Aug;57(8):1753-4. doi: 10.3109/10428194.2016.1154962. PubMed PMID: 26998891. (IF 2020: 3.28)
134. Mylam KJ, Michaelsen TY, Hutchings M, Jacobsen Pulczynski E, Pedersen LM, Braendstrup P, Gade IL, Eberlein TR, Gang AO, Bøgsted M, Brown PN, **El-Galaly TC**. Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study. *Br J Haematol*. 2016 Feb 23. doi: 10.1111/bjh.13988. [Epub ahead of print] PubMed PMID: 26913572. (IF 2022: 6.5)
135. Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, Johnsen HE, Bøgsted M, Jerkeman M, **El-Galaly TC** (§). No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. *Br J Haematol*. 2016 Feb 5. doi: 10.1111/bjh.13943. [Epub ahead of print] PubMed PMID: 26846879. (IF 2022: 6.5)
136. **El-Galaly TC**, Hutchings M, Villa D. Reply to H.J Adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?". *Am J Hematol*. 2016 Feb;91(2):E2-3. doi: 10.1002/ajh.24239. PubMed PMID: 26572073. (IF 2021:13.268)
137. Svendsen P, **El-Galaly TC**, Dybkær K, Bøgsted M, Laursen MB, Schmitz A, Jensen P, Johnsen HE. The application of human phase 0 microdosing trials: A systematic review and perspectives. *Leuk Lymphoma*. 2016;57(6):1281-90. doi: 10.3109/10428194.2015.1101097. Review. PubMed PMID: 26428262. (IF 2020: 3.28)
138. Jensen P, Bendtsen MD, Johnsen HE, Bøgsted M, **El-Galaly TC**. To maintain or not, that is the question. *Br J Haematol*. 2016 Jul;174(2):321-2. doi: 10.1111/bjh.13761. PubMed PMID: 26403171. (IF 2022: 6.5)

2015

139. **El-Galaly TC**, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Székely E, Mylam KJ, Hjalmar V, Johnsen HE, Bøgsted M, Jerkeman M. Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. *J Clin Oncol*. 2015 Dec 1;33(34):3993-8. doi: 10.1200/JCO.2015.62.0229. Epub 2015 Oct 5. PubMed PMID: 26438115. (IF 2021: 50.717)
140. **El-Galaly TC**#, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, de Nully Brown P, Loft A, Iyer V, Johnsen HE, Savage KJ, Connors JM, Hutchings M. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. *Am J Hematol*. 2015 Nov;90(11):1041-6. doi: 10.1002/ajh.24169. PubMed PMID: 26260224. (IF 2021:13.268)

141. **El-Galaly TC**, Pedersen MB, Hutchings M, Mylam KJ, Madsen J, Gang AO, Bøgsted M, de Nully Brown P, Loft A, Nielsen AL, Hendel HW, Iyer V, Gormsen LC. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients. *Am J Hematol*. 2015 Nov;90(11):975-80. doi: 10.1002/ajh.24128. Epub 2015 Aug 14. PubMed PMID: 26201505. (IF 2021:13.268)
142. Falgreen S, Dybkær K, Young KH, Xu-Monette ZY, **El-Galaly TC**, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Bøgsted M. Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. *BMC Cancer*. 2015 Apr 8;15:235. doi: 10.1186/s12885-015-1237-6. PubMed PMID: 25881228; PubMed Central PMCID: PMC4396063. (IF 2020: 4.43)
143. Dybkær K, Bøgsted M, Falgreen S, Bødker JS, Kjeldsen MK, Schmitz A, Bilgrau AE, Xu-Monette ZY, Li L, Bergkvist KS, Laursen MB, Rodrigo-Domingo M, Marques SC, Rasmussen SB, Nyegaard M, Gaihede M, Møller MB, Samworth RJ, Shah RD, Johansen P, **El-Galaly TC**, Young KH, Johnsen HE. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. *J Clin Oncol*. 2015 Apr 20;33(12):1379-88. doi: 10.1200/JCO.2014.57.7080. PubMed PMID: 25800755; PubMed Central PMCID: PMC4397280 (IF 2021: 50.717)
144. **El-Galaly TC**, Bilgrau AE, de Nully Brown P, Mylam KJ, Ahmad SA, Pedersen LM, Gang AO, Bentzen HH, Juul MB, Bergmann OJ, Pedersen RS, Nielsen BJ, Johnsen HE, Dybkaer K, Bøgsted M, Hutchings M. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. *Br J Haematol*. 2015 May;169(3):435-44. doi: 10.1111/bjh.13316. Epub 2015 Feb 23. PubMed PMID: 25709094. (IF 2022: 6.5)
145. **El-Galaly TC**, Hutchings M. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. *Cancer Treat Res*. 2015;165:125-46. doi: 10.1007/978-3-319-13150-4_5. Review. PubMed PMID: 25655608. (IF not available)
146. **El-Galaly TC**, Bilgrau AE, Gaarsdal E, Klausen TW, Pedersen LM, Nielsen KR, Bæch J, Bøgsted M, Dybkær K, Johansen JS, Johnsen HE. Circulating tumor necrosis factor- α and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma. *Leuk Lymphoma*. 2015;56(8):2476-8. doi: 10.3109/10428194.2014.1001984. Epub 2015 Feb 24. PubMed PMID: 25563560. (IF 2020: 3.28)

2014

147. Laursen MB, Falgreen S, Bødker JS, Schmitz A, Kjeldsen MK, Sørensen S, Madsen J, **El-Galaly TC**, Bøgsted M, Dybkær K, Johnsen HE; Myeloma Stem Cell Network. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. *Exp Hematol*. 2014 Nov;42(11):927-38. doi: 10.1016/j.exphem.2014.07.263. Review. PubMed PMID: 25072621. (IF 2020: 5.133)
148. Schjelderup P, **El-Galaly TC**, Frøkjær JB, Ring T. Acute respiratory failure during first cyclophosphamide infusion in a patient with systemic lupus erythematosus. *Z Rheumatol*. 2014 Dec;73(10):939-41. doi: 10.1007/s00393-014-1381-4. PubMed PMID: 24830677.
149. **El-Galaly TC**, Mylam KJ, Bøgsted M, Brown P, Rossing M, Gang AO, Haglund A, Arboe B, Clausen MR, Jensen P, Pedersen M, Bukh A, Jensen BA, Poulsen CB, d'Amore F, Hutchings M. Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. *Am J Hematol*. 2014 Jun;89(6):575-80. doi: 10.1002/ajh.23688. Epub 2014 Feb 24. PubMed PMID: 24493389. (IF 2021:13.268)
150. **El-Galaly TC**, Hutchings M, Mylam KJ, Brown P, Bukh A, Johnsen HE, Kamper P, Loft A, Iyer V, Gormsen LC, Nielsen AL, Bøgsted M, d'Amore F.

Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. *Leuk Lymphoma*. 2014 Oct;55(10):2349-55. doi: 10.3109/10428194.2013.875169. Epub 2014 Feb 24. PubMed PMID: 24354682. (IF 2020: 3.28)

151. Mylam KJ, **El-Galaly TC**, Hutchings M, Brown P, Himmelstrup B, Gerke O, Gillstrøm D, Sillesen IB, Munksgaard L, Pedersen BB, Christiansen I, Jensen P, Nielsen AL, Pedersen LM. Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2014 Jul;55(7):1563-9. doi: 10.3109/10428194.2013.850165. PubMed PMID: 24144339. (IF 2020: 3.28)

2013

152. **El-Galaly TC**, Severinsen MT, Overvad K, Steffensen R, Vistisen AK, Tjønneland A, Kristensen SR. Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish case-cohort study. *Br J Haematol*. 2013 Mar;160(6):838-41. doi: 10.1111/bjh.12132. Epub 2012 Nov 15. PubMed PMID: 23150947. (IF 2022: 6.5)

2012

153. **El-Galaly TC**, d'Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, Specht L, Loft A, Iyer V, Hjorthaug K, Nielsen AL, Christiansen I, Madsen C, Johnsen HE, Hutchings M. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. *J Clin Oncol*. 2012 Dec 20;30(36):4508-14. doi: 10.1200/JCO.2012.42.4036. Epub 2012 Nov 13. PubMed PMID: 23150698. (IF 2021: 50.717)
154. **El-Galaly TC**, Kristensen SR, Overvad K, Steffensen R, Tjønneland A, Severinsen MT. Interaction between blood type, smoking and factor V Leiden mutation and risk of venous thromboembolism: a Danish case-cohort study. *J Thromb Haemost*. 2012 Oct;10(10):2191-3. doi: 10.1111/j.1538-7836.2012.04772.x. PubMed PMID: 22577971. (IF 2020: 5.824)
155. **El-Galaly TC**, Mylam KJ, Brown P, Specht L, Christiansen I, Munksgaard L, Johnsen HE, Loft A, Bukh A, Iyer V, Nielsen AL, Hutchings M. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. *Haematologica*. 2012 Jun;97(6):931-6. doi: 10.3324/haematol.2011.056010. Epub 2011 Dec 29. PubMed PMID: 22207683; PubMed Central PMCID: PMC3366662. (IF 2022: 10.1)

2011

156. **El-Galaly TC**, Prakash V, Christiansen I, Madsen J, Johansen P, Boegsted M, Johnsen HE, Bukh A. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. *Leuk Lymphoma*. 2011 Apr;52(4):597-603. doi: 10.3109/10428194.2010.547642. Epub 2011 Feb 14. PubMed PMID: 21314488. (IF 2020: 3.28)
157. **El-Galaly TC**, Gregersen H, Bukh A. [Good's syndrome with lymphopenia and neutropenia]. *Ugeskr Laeger*. 2011 Jan 24;173(4):280-1. Danish. PubMed PMID: 21262174. (IF not available)

2007

158. **El-Galaly TC**, Keldsen N. [Picture of the month: vena cava superior syndrome].

Ugeskr Laeger. 2007 Sep 10;169(37):3118. Danish. PubMed PMID: 17915351.
(IF not available)

2. Monographs

2017

El-Galaly TC. Staging and Disease Surveillance in Hodgkin and Non-Hodgkin Lymphoma. Medical doctoral dissertation defence, 21 April 2017, Aalborg University. Published April 2017; pp.81

3. Book chapters

2021

EI - Galaly TC, Cottureau A-S, Condoluci A, Rossi D, Zaucha JM, Sureda A, Cheson B, Gallamini A. Hodgkin Lymphoma: Recent Progress in Overall Management. In: Gallamini A, Juwied M, editors. Lymphoma [Internet]. Brisbane (AU): Exon Publications; 2021 [cited 2022 Jan 26]. Available from:<https://exonpublications.com/index.php/exon/article/view/448>

2019

Kjeldsen L, Abildgaard N, Andersen MK, Birgens H, Brown PDN, **El-Galaly T C,** Frederiksen H, Grønbæk K, Hutchings M, Leinøe EB, Nielsen OJ, Niemann CU, Overgaard U, Sengeløv H, Stentoft J. Blodsygdomme. 2019, Medicinsk Kompendium, Schaffalitzky de Muckadell, O. B., Hastrup Svendsen, J. & Vilstrup, H. (red.). 19. udg. København: Munksgaard , s. 1605-1720.

2016

Hutchings M, Loft A, **El-Galaly TC.** PET/CT for HL Staging. In Gallamini A (red.) PET Scan in Hodgkin Lymphoma: Role in Diagnosis, Prognosis, and Treatment. Switzerland: Springer Publishing Company. 2016. s. 1-13 https://doi.org/10.1007/978-3-319-31797-7_1

2015

El-Galaly TC, Hutchings M. Imaging of non-hodgkin lymphomas: diagnosis and response-adapted strategies. In Evens AM, Blum KA (red.) Non-Hodgkin Lymphoma: Pathology, Imaging, and Current Therapy. Schweiz: Springer. 2015. s. 125-146. (Cancer Treatment and Research; Nr. 165). https://doi.org/10.1007/978-3-319-13150-4_5

Projects

I have been involved in several clinical trials in lymphoma, as investigator and co-investigator. I have also been involved as trial lead in global trials in industry.

In recent years, I have not taken any PI roles due to my role in the EMA SAG.

Memberships

OTHER CURRENT OCCUPATIONS

- 2023- Cancer center auditor, OECI - Organisation of European Cancer Institutions
- 2023- Referee, medicin.dk, hematology/oncology
- 2022- Vicechair, Scientific Advisory Group (SAG) Oncology/Haematology, European Medicines Agency (EMA)
- 2022- Chair, Danish National Medical Research Ethics Committee (VMK)
- 2021- Expert assessor, second opinion panel hematology, Danish Health Authority
- 2017- Adjudicator Danish Universities, internal medicine, and emergency medicine
- 2016- Expert assessor in hematology, patient compensation assessments

OTHER AFFILIATIONS

- 2022- Adjunct professor in Hematology at University of Southern Denmark, Odense, Denmark

2021- Affiliated researcher, Department of Cancer Epidemiology, Karolinska Institutet, Stockholm

Current memberships of scientific and clinical working groups

2024- Public Health Emergencies (PHE) Ethics Advisory Group, EMA, member

2024- European Specialized Expert Community (ESEC), Methodology, EMA, member

2024- Task Force for Diversity, Equity, and Inclusion, European Hematology Association (EHA), chair

2023- Coalition for Reducing Bureaucracy in Clinical Trials, member of ethics working group

2023- Accelerating Clinical Trials in the EU (ACT EU) multi-stakeholder platform Advisory Group, permanent member for EHA

2023- EHA representative in Cancer Medicines Forum

2023- European Affairs Committee, EHA, member

2023- Danish Lymphoma Group (DLG), chair

2022- ESEC, Hematology/oncology, EMA, member

2022- European Lymphoma Institute (ELI), board member

2022- Danish working group for diffuse large B cell lymphoma, DLG, chair

2021- Epidemiology working group, Nordic Lymphoma Group (NLG), chair

2021- Danish working committee for CNS lymphoma, DLG, member

2021- Nordic Lymphoma Working Group for CNS lymphoma, NLG, board member

Other Relevant Information

Peer Review Work for Scientific Journals and Editorial Boards

Peer reviewer for Acta Oncologica, Aging and Disease, American Journal of Hematology, Annals of Hematology, Annals of Oncology, Blood, Blood Advances, BMJ Quality & Safety, British Medical Journal, Bone Marrow Transplantation, British Journal of Cancer, British Journal of Hematology, Cancer, Cancer Medicine, Cancers, European Journal of Cancer, European Journal of Hematology, Future Oncology, Haematologica, Hematological Oncology, Journal of Nuclear Medicine, Lancet Haematology, Lancet Oncology, Leukemia, Leukemia and Lymphoma, Nature Communications, Scientific Reports.

Abstract reviewer

Coordinating abstract reviewer EHA 2024 “Health economics and ethics”. Coordinating abstract reviewer ASH 2023.

Expert committee member, 7th and 8th International Workshop on PET in Lymphoma and Myeloma, 2018 and 2021.

Abstract reviewer for EHA 2018 & 2022, and ASH 2019 & 2022, including session chairing at conferences.

Editorial board participation

2023- Associate Editor, ESMO Real World Data and Digital Oncology

2021- Editorial Board, British Journal of Haematology

2021- Advisory Board, Acta Oncologica

2021- Editorial Board, Leukemia and Lymphoma

2018- Editorial Board, Annals of Lymphoma

2021-2023 Editorial Board, Journal of Personalized Medicine

2016-2019 Editorial board, Best Practice Hematology